JOIN THE RAKUTEN MEDICAL TEAM!
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox™ technology platform. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. Headquartered in the United States, Rakuten Medical has 6 locations in 5 countries, Japan, the Netherlands, Germany and Taiwan.
We follow the science, work for the patients, and hunt for innovation. Our culture embodies collaboration, transparency, and hard-work. We are building a company unlike any other biotechnology entity. Join us!
- Excellent health, vision and dental plans
- Life insurance
- Flexible Paid Time Off
- Competitive benefits and compensation
- Stock options
We are Rakuten Medical, Inc., a privately funded, clinical stage, global Biopharmaceutical Company with locations in San Mateo, CA (Corporate Headquarters) and San Diego, CA (R&D Science Park), and regional offices in Japan, Taiwan, The Netherlands, and Germany.
Our mission is to offer new, safe, and effective cancer treatment options that could transform and improve the lives of patients. Rakuten Medical was created out of passion, ambition, and the motivating strength to take on the battle against a disease that affects millions across the world – cancer. Rakuten Medical embraces a culture of compassion. We abide by our promise to develop effective, safe and innovative therapies for patients as soon as scientifically possible, without delay, to extend and improve cancer treatment worldwide. Our slogan is “CONQUERING Cancer. For LIFE”.
We are supported by investors that have the commitment to build a fully integrated R&D and commercial biopharmaceutical company to innovate, develop, and commercialize cutting edge cancer therapies.
Currently we are developing therapies based on a novel proprietary technology platform that utilizes antibodies conjugated with payloads that are specifically activated at the tumor site. Our first clinical product is in Phase 3 pivotal clinical testing to treat terminal cancer patients. This is a first-in-class product with unique pharmacological activity and with the potential to have a broad impact in cancer. Given the rapid progression of the clinical studies we are quickly growing our teams to build and enhance in-house expertise with the intent to expand our R&D operations, clinical programs and prepare for the commercialization of our products.